Journal article
Warfarin-5-FU Interaction - A Consecutive Case Series
Pharmacotherapy : official journal of the American College of Clinical Pharmacy, Vol.19(12), pp.1445-1449
12/1999
DOI: 10.1592/phco.19.18.1445.30897
Abstract
Five patients from a single institution received concomitant warfarin and 5-fluorouracil (5-FU) during a 3-year period. The mean weekly warfarin dose before starting chemotherapy was 40.66 mg and during chemotherapy it was 24 mg (p=0.0026). All patients required a warfarin dosage reduction (range 18–74%, mean 44%). Two patients were hospitalized, one with a major retroperitoneal bleed, the other for fresh-frozen plasma administration and observation. Maximum international normalized ratios (INRs) ranged from 3.66–23.7. This series confirms a common, clinically significant interaction between warfarin and 5-FU. An interaction between capecitabine, the orally available prodrug of 5-FU, and warfarin also has been reported. We recommend weekly monitoring of prothrombin time and INR for all patients receiving concomitant warfarin and 5-FU or capecitabine.
Details
- Title: Subtitle
- Warfarin-5-FU Interaction - A Consecutive Case Series
- Creators
- Jill M. Kolesar - University of Wisconsin–MadisonCarrie L. Johnson - University of CincinnatiBetty L. Freeberg - William S. Middleton Memorial Veterans HospitalJordan D. Berlin - Vanderbilt University Medical CenterJoan H. Schiller - University of Wisconsin–Madison
- Resource Type
- Journal article
- Publication Details
- Pharmacotherapy : official journal of the American College of Clinical Pharmacy, Vol.19(12), pp.1445-1449
- Publisher
- Blackwell Publishing Ltd; Oxford, UK
- DOI
- 10.1592/phco.19.18.1445.30897
- ISSN
- 0277-0008
- eISSN
- 1875-9114
- ISSN
- 0277-0008
- eISSN
- 1875-9114
- Number of pages
- 5
- Language
- English
- Date published
- 12/1999
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696545602771
Metrics
1 Record Views